MedTrace Logo

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

NCT00836914 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-10-23

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effect of CAL-101 in subjects with allergic rhinitis.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

CAL-101

CAL-101 100mg capsules administered orally twice a day (BID) for 7 days

DRUG

Placebo

Placebo capsules administered orally BID for 7 days

Sponsors & Collaborators

Principal Investigators

  • Friedrich Horak, MD · Vienna Challenge Chamber

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00836914 on ClinicalTrials.gov